Pharmaceuticals, Biotechnology and Life Sciences
Sanofi and Lexicon Pharmaceuticals have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
Colonis, part of Quantum Pharma’s newly formed Niche Pharmaceuticals division, has launched its in-licensed range of patented medical devices to treat…
Sanofi and Hanmi Pharmaceutical Co., Ltd. announced Thursday a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.
Redx, the drug discovery and development company, has made two senior management appointments.
The company on Thursday said that Nicholas Adams is new as Chief Business Officer and Dr Matilda Bingham has been promoted to Executive Director of Redx Oncology Ltd, the Group’s oncology subsidiary.
Verona Pharma has completed patient enrolment for the Phase IIa dose-finding study of RPL554 in asthma and the Phase IIa combination study of RPL554 in chronic obstructive pulmonary disease (COPD), in which the drug is being administered in addition to standard of care bronchodilators.
OptiBiotix Health has announced the filing of two new patents covering its cholesterol reducing product. This increases the number of patents from nine to eleven.
Finland’s Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has entered into an agreement with Swiss-based Selexis SA for producing Novel Cancer Immunotherapy Clevegen.
Bayer CropScience has reached an important milestone towards the market introduction of its innovative insecticide Sivanto prime in Europe.
Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx(TM) (secukinumab)…
Dechra has announced that on the closing date of its Takeover Offer to acquire the shares in Genera not owned by…